Wang Lina, Li Hao, Yang Zhongyuan, Chen Wenkuan, Zhang Quan
Graduate, Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center and State Key Laboratory of Oncology in South China, Guangzhou, China.
Associate Professor, Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center and State Key Laboratory of Oncology in South China, Guangzhou, China.
J Oral Maxillofac Surg. 2015 Sep;73(9):1860-4. doi: 10.1016/j.joms.2015.03.016. Epub 2015 Mar 19.
To discuss the outcomes of primary squamous cell carcinoma (SCC) of the major salivary glands treated by surgery with or without postoperative adjuvant radiotherapy.
We performed a retrospective analysis of 579 cases with malignancy originating in the major salivary glands. A total of 34 cases were eligible for the present study. The outcomes were analyzed in terms of disease failure patterns and survival rates between the 2 treatment groups.
The treatment was surgery alone in 16 patients and a combination of surgery and postoperative adjuvant radiotherapy in 18. The locoregional recurrence rate was 43.8% in the surgery group and 22.2% in the surgery plus radiotherapy group. The distant metastasis rate was 6.3% in the surgery group and 44.4% in the surgery plus radiotherapy group. The 5-year disease-specific survival and disease-free survival (DFS) rate for all patients was 50.3% and 35.3%, respectively. The 5-year disease-specific survival rate was 48.9% in the surgery group and 48.2% in the surgery plus radiotherapy group. The 5-year DFS rate was 25.0% in the surgery group and 31.2% in the surgery plus radiotherapy group. The log-rank test showed no significant differences in the disease-specific survival or DFS rates between the 2 groups (P = .724 for disease-specific survival and P = .269 for DFS).
Planned postoperative adjuvant radiotherapy is anticipated to be able to improve locoregional control rates and DFS for patients with primary SCC of the major salivary glands.
探讨手术联合或不联合术后辅助放疗治疗大唾液腺原发性鳞状细胞癌（SCC）的疗效。
我们对579例起源于大唾液腺的恶性肿瘤患者进行了回顾性分析。共有34例患者符合本研究条件。根据疾病失败模式和两个治疗组之间的生存率对结果进行分析。
16例患者仅接受手术治疗，18例患者接受手术联合术后辅助放疗。手术组的局部区域复发率为43.8%，手术加放疗组为22.2%。手术组的远处转移率为6.3%，手术加放疗组为44.4%。所有患者的5年疾病特异性生存率和无病生存率（DFS）分别为50.3%和35.3%。手术组的5年疾病特异性生存率为48.9%，手术加放疗组为48.2%。手术组的5年DFS率为25.0%，手术加放疗组为31.2%。对数秩检验显示两组之间的疾病特异性生存率或DFS率无显著差异（疾病特异性生存率P = 0.724，DFS为P = 0.269）。
预计计划性术后辅助放疗能够提高大唾液腺原发性SCC患者的局部区域控制率和DFS。
